Smad4 haploinsufficiency in mouse models for intestinal cancer
The Smad4 +/E6sad mouse carries a null mutation in the endogenous Smad4 gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majo...
Gespeichert in:
Veröffentlicht in: | Oncogene 2006-03, Vol.25 (13), p.1841-1851 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The
Smad4
+/E6sad
mouse carries a
null
mutation in the endogenous
Smad4
gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majority of the tumors appear at 9 months of age, somatic loss of the wild-type
Smad4
allele occurs only at later stages of tumor progression. Hence, haploinsufficiency underlies
Smad4
-driven tumor initiation in the GI tract. As both the
Apc
and
Smad4
tumor suppressor genes map to mouse chromosome 18, we have bred
Smad4
+/E6sad
with the
Apc
+/1638N
model to generate two distinct compound heterozygous lines carrying both mutations either
in cis
(CAS) or
in trans
(TAS). Strikingly, both models show increased tumor multiplicities when compared with the single mutant littermates, although CAS mice are more severely affected and became moribund at only 5–6 weeks of age. Phenotypic and molecular analyses indicate that
Smad4
haploinsufficiency is sufficient to significantly affect tumor initiation and progression both prior to and upon loss of Apc function. Moreover, complete loss of Smad4 strongly enhances
Apc
-driven tumor formation. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/sj.onc.1209226 |